About: Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $13.17 (+6.43%)
HELP NYSE Cybin Inc. Common Stock
Cybin Inc. Common Stock share price
HELP price activity
Last Price
$13.170
Change (24hr)
0.80 USD (6.43%)
Volume
514.55K
Volume (4w avg)
-
Open
$13.02
Day Range
$12.76 - $13.38
Previous Close
$12.37
Last Trade
21 Sep, 2:00 pm GMT+0
Delayed
21 Sep, 2:00 pm GMT+0
HELP price performance
Delayed
21 Sep, 2:00 pm GMT+0
HELP Market Signals